Pneumococcal conjugate vaccine for adults: "It's tough to make predictions, ...".
نویسندگان
چکیده
The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed for adults in 2011. Data from the largest randomised controlled trial (RCT) on a pneumococcal vaccine published to date (the CAPITA study) show a vaccine efficacy of 45.6% for pneumonia caused by the 13 vaccine serotypes, including 45.0% for non-bacteraemic pneumonia [2]. Do these data justify the general use of PCV13 in adults? MANGEN et al. [1] conducted economic modelling mainly based on the data of the CAPITA study that showed that PCV13 in adults is highly cost-effective. However, vaccination of infants, the main reservoir of pneumococci, with conjugate vaccines has resulted in herd protection effects, i.e. also decreased prevalence of the serotypes contained in vaccine in adults.
منابع مشابه
Nasopharyngeal Pneumococcal Colonization among Children after Pneumococcal Conjugate Vaccine Introduction
World Health Organization has recommended all countries to introduction of Pneumococcal Conjugate Vaccine (PCV) in routine immunization schedule, especially those countries with higher rate of mortality in children. However, Islamic Republic of Iran and more than 50 other countries including Algeria, Antigua and Barbuda, Belarus, Belize, Bhutan, Bosnia and Herzegovina, Brunei Darussalam, Cabo V...
متن کاملGlobal Coverage of Pneumococcal Conjugate Vaccine (PCV) and Serotype Distribution after Receiving Vaccine among Targeted PCV Vaccine Countries: A Systematic Review
Background and Objectives: After the introduction of the pneumococcal vaccine, an increase has been observed in the disease due to nonspecific stereotypes of the vaccine. This study was conducted to determine the spatial distribution of pneumococcal vaccine coverage and common stereotypes of streptococcus pneumonia after vaccine introduction in the vaccine recipient countries. Methods: The ...
متن کاملPneumococcal Disease Prevention Among Adults: Strategies for the Use of Pneumococcal Vaccines.
Use of the pneumococcal conjugate vaccines among children in the U.S. since 2000 has dramatically reduced pneumococcal disease burden among adults. Significant vaccine-preventable morbidity and mortality from pneumococcal infections still remains, especially among older adults. The U.S. Advisory Committee on Immunization Practices (ACIP) has recently recommended the routine use of both pneumoco...
متن کاملUse of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults aged ≥65 years. PCV13 should be administered in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax23, Merck & Co., Inc.]), the vacc...
متن کاملHow Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda
Background To date, research on priority-setting for new vaccines has not adequately explored the influence of the global, national and sub-national levels of decision-making or contextual issues such as political pressure and stakeholder influence and power. Using Kapiriri and Martin’s conceptual framework, this paper evaluates priority setting for new vaccines in Uganda at national and sub-na...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The European respiratory journal
دوره 46 5 شماره
صفحات -
تاریخ انتشار 2015